BACKGROUND: Peripheral neuropathy is the dose limiting toxicity of bortezomib in patients with multiple myeloma (MM). OBJECTIVES: To examine the safety, feasibility and efficacy of acupuncture in reducing bortezomib-induced peripheral neuropathy (BIPN) symptoms. METHODS:Patients with MM experiencing persistent BIPN ≥grade 2 despite adequate medical intervention and discontinuation ofbortezomib received 10 acupuncture treatments for 10 weeks (2×/week for 2 weeks, 1×/week for 4 weeks, and then biweekly for 4 weeks). Responses were assessed by the Clinical Total Neuropathy Score (TNSc), Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire, and the Neuropathy Pain Scale (NPS). Repeated-measures analysis of variance was used to test for monotonic decline in scores on each of the measures. Serial serum levels of proinflammatory and neurotrophic cytokines were obtained at baseline and weeks 1, 2, 4, 8, and 14. RESULTS:Twenty-seven patients with MM were enrolled in the trial. There were no adverse events associated with the acupuncture treatments. TNSc data were deemed invalid and therefore were not reported. At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction suggesting decreased pain, and improved function (P values were <.0001 for both FACT/GOG-Ntx and NPS at weeks 10 and 14). However, nerve conduction studies did not significantly change between baseline assessment and end of study. There was no correlation in serum cytokines for responders versus none responders. CONCLUSIONS:Acupuncture is safe, feasible and produces subjective improvements in patients' symptoms. A follow-up randomized controlled trial is warranted.
RCT Entities:
BACKGROUND:Peripheral neuropathy is the dose limiting toxicity of bortezomib in patients with multiple myeloma (MM). OBJECTIVES: To examine the safety, feasibility and efficacy of acupuncture in reducing bortezomib-induced peripheral neuropathy (BIPN) symptoms. METHODS:Patients with MM experiencing persistent BIPN ≥grade 2 despite adequate medical intervention and discontinuation of bortezomib received 10 acupuncture treatments for 10 weeks (2×/week for 2 weeks, 1×/week for 4 weeks, and then biweekly for 4 weeks). Responses were assessed by the Clinical Total Neuropathy Score (TNSc), Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire, and the Neuropathy Pain Scale (NPS). Repeated-measures analysis of variance was used to test for monotonic decline in scores on each of the measures. Serial serum levels of proinflammatory and neurotrophic cytokines were obtained at baseline and weeks 1, 2, 4, 8, and 14. RESULTS: Twenty-seven patients with MM were enrolled in the trial. There were no adverse events associated with the acupuncture treatments. TNSc data were deemed invalid and therefore were not reported. At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction suggesting decreased pain, and improved function (P values were <.0001 for both FACT/GOG-Ntx and NPS at weeks 10 and 14). However, nerve conduction studies did not significantly change between baseline assessment and end of study. There was no correlation in serum cytokines for responders versus none responders. CONCLUSIONS: Acupuncture is safe, feasible and produces subjective improvements in patients' symptoms. A follow-up randomized controlled trial is warranted.
Authors: N Lynn Henry; Mousumi Banerjee; Max Wicha; Catherine Van Poznak; Jeffrey B Smerage; Anne F Schott; Jennifer J Griggs; Daniel F Hayes Journal: Cancer Date: 2011-06-20 Impact factor: 6.860
Authors: M Kay Garcia; Jennifer McQuade; Richard Lee; Robin Haddad; Michael Spano; Lorenzo Cohen Journal: Curr Oncol Rep Date: 2014-12 Impact factor: 5.075
Authors: Farah Z Zia; Oluwadamilola Olaku; Ting Bao; Ann Berger; Gary Deng; Arthur Yin Fan; Mary K Garcia; Patricia M Herman; Ted J Kaptchuk; Elena J Ladas; Helene M Langevin; Lixing Lao; Weidong Lu; Vitaly Napadow; Richard C Niemtzow; Andrew J Vickers; Xin Shelley Wang; Claudia M Witt; Jun J Mao Journal: J Natl Cancer Inst Monogr Date: 2017-11-01
Authors: Heather Greenlee; Katherine D Crew; Jillian Capodice; Danielle Awad; Donna Buono; Zaixing Shi; Anne Jeffres; Sharon Wyse; Wendy Whitman; Meghna S Trivedi; Kevin Kalinsky; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2016-03-25 Impact factor: 4.872
Authors: Jacqueline Zayas; Kathryn J Ruddy; Janet E Olson; Fergus J Couch; Brent A Bauer; Molly J Mallory; Ping Yang; David Zahrieh; Arjun P Athreya; Charles L Loprinzi; Elizabeth J Cathcart-Rake Journal: Support Care Cancer Date: 2020-04-06 Impact factor: 3.603
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315